Published in J Biol Chem on December 05, 1997
Imp-L2, a putative homolog of vertebrate IGF-binding protein 7, counteracts insulin signaling in Drosophila and is essential for starvation resistance. J Biol (2008) 1.65
Low birthweight and adult insulin resistance: the "catch-up growth" hypothesis. Arch Dis Child Fetal Neonatal Ed (1999) 1.32
A hippocampal insulin-growth factor 2 pathway regulates the extinction of fear memories. EMBO J (2011) 1.20
Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia. Mol Pathol (2002) 0.94
Circulating IGF-binding protein 7 (IGFBP7) levels are elevated in patients with endometriosis or undergoing diabetic hemodialysis. Reprod Biol Endocrinol (2008) 0.93
EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. Am J Physiol Gastrointest Liver Physiol (2005) 0.92
Proteins on the catwalk: modelling the structural domains of the CCN family of proteins. J Cell Commun Signal (2009) 0.92
Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC). Mol Ther (2013) 0.92
Evaluation of IGFBP-7 DNA methylation changes and serum protein variation in Swedish subjects with and without type 2 diabetes. Clin Epigenetics (2013) 0.87
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma. J Hematol Oncol (2015) 0.85
Nutritionally-induced catch-up growth. Nutrients (2015) 0.83
Proteomic analysis identifies insulin-like growth factor-binding protein-related protein-1 as a podocyte product. Am J Physiol Renal Physiol (2010) 0.82
Modeling the Insulin-Like Growth Factor System in Articular Cartilage. PLoS One (2013) 0.81
Insulin-like growth factor system gene expression in women with type 2 diabetes and breast cancer. J Clin Pathol (2003) 0.80
Metformin stimulates IGFBP-2 gene expression through PPARalpha in diabetic states. Sci Rep (2016) 0.80
IGF-Binding Protein 2 - Oncogene or Tumor Suppressor? Front Endocrinol (Lausanne) (2015) 0.79
Role of insulin-like growth factor binding protein-3 in glucose and lipid metabolism. Ann Pediatr Endocrinol Metab (2013) 0.79
IGFBP-rP1, a potential molecule associated with colon cancer differentiation. Mol Cancer (2010) 0.79
Expression of IGFBP7 mRNA in corticotrophs in the anterior pituitary of adrenalectomized rats. J Histochem Cytochem (2010) 0.78
Stage debut for the elusive Drosophila insulin-like growth factor binding protein. J Biol (2008) 0.77
Role of IGFBP7 in Diabetic Nephropathy: TGF-β1 Induces IGFBP7 via Smad2/4 in Human Renal Proximal Tubular Epithelial Cells. PLoS One (2016) 0.77
Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population. Sci Rep (2015) 0.77
A crayfish insulin-like-binding protein: another piece in the androgenic gland insulin-like hormone puzzle is revealed. J Biol Chem (2013) 0.77
IGFBPrP1 induces liver fibrosis by inducing hepatic stellate cell activation and hepatocyte apoptosis via Smad2/3 signaling. World J Gastroenterol (2014) 0.77
Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome. BMC Cancer (2015) 0.76
Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy. Acta Neuropathol (2015) 0.76
Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.76
Interaction between IGFBP7 and insulin: a theoretical and experimental study. Sci Rep (2016) 0.75
Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. BMC Cardiovasc Disord (2016) 0.75
Understanding Insulin Endocrinology in Decapod Crustacea: Molecular Modelling Characterization of an Insulin-Binding Protein and Insulin-Like Peptides in the Eastern Spiny Lobster, Sagmariasus verreauxi. Int J Mol Sci (2017) 0.75
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (1991) 9.89
Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature (1995) 6.33
Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev (1995) 4.22
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev (1999) 3.54
Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science (1988) 3.40
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem (1991) 2.79
FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem (2000) 2.58
The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol (1988) 2.36
A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem (1994) 2.35
Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci U S A (1989) 2.28
Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. J Clin Endocrinol Metab (1998) 2.17
Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells. Blood (1977) 2.05
Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem (1999) 2.00
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol (1997) 1.90
Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci U S A (1997) 1.88
The multistep proteolytic maturation pathway utilized by vaccinia virus P4a protein: a degenerate conserved cleavage motif within core proteins. Virology (1991) 1.86
Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol (1996) 1.84
Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol (1995) 1.83
Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: evidence for further genetic heterogeneity in this syndrome. Proc Natl Acad Sci U S A (1988) 1.76
Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet (1989) 1.74
Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem (1992) 1.73
Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. J Bone Miner Res (1998) 1.69
Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. Endocrinology (1998) 1.66
Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation. Clin Nephrol (1998) 1.61
Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab (1995) 1.59
Both human pituitary growth hormone and recombinant DNA-derived human growth hormone cause insulin resistance at a postreceptor site. J Clin Endocrinol Metab (1982) 1.59
Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem (1996) 1.58
Prospective clinical trial of human growth hormone in short children without growth hormone deficiency. J Pediatr (1984) 1.55
Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem (1995) 1.54
Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab (1992) 1.53
Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol (2000) 1.53
Insulin-like growth factor-mediated muscle differentiation: collaboration between phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin. J Biol Chem (2001) 1.51
Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem (1993) 1.49
Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem (1998) 1.48
The androgen receptor: an overview. Recent Prog Horm Res (1994) 1.48
Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem (1995) 1.45
Mechanics and dynamics of the strain-induced M1-M2 structural phase transition in individual VO₂ nanowires. Nano Lett (2011) 1.42
Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol (1995) 1.41
Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab (1991) 1.40
Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol (1990) 1.40
A frameshift mutation destabilizes androgen receptor messenger RNA in the Tfm mouse. Mol Endocrinol (1991) 1.39
Hormone-dependent transactivation by the human androgen receptor is regulated by a dnaJ protein. J Biol Chem (1995) 1.39
A single base mutation in the androgen receptor gene causes androgen insensitivity in the testicular feminized rat. J Biol Chem (1990) 1.37
Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol (1999) 1.32
Environmental antiandrogens: developmental effects, molecular mechanisms, and clinical implications. J Mol Med (Berl) (1997) 1.31
Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem (1993) 1.27
Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group. J Clin Endocrinol Metab (2000) 1.26
Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab (1993) 1.26
Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol (1994) 1.25
Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res (1996) 1.25
Short stature and pubertal delay in male adolescents with cystic fibrosis. Androgen treatment. Am J Dis Child (1984) 1.23
Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology (1990) 1.23
Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene (1997) 1.22
Complete androgen insensitivity due to deletion of exon C of the androgen receptor gene highlights the functional importance of the second zinc finger of the androgen receptor in vivo. Mol Endocrinol (1992) 1.20
Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem (1976) 1.20
Digital respirosonography. New images of lung sounds. Chest (1989) 1.20
Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-rP3/NovH), an additional member of the IGFBP Superfamily. J Clin Endocrinol Metab (1999) 1.19
Treatment of Turner's syndrome with recombinant human growth hormone (somatrem). Acta Paediatr Scand Suppl (1988) 1.19
Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int (1986) 1.18
Characterization of the somatomedin-C/insulin-like growth factor I (SM-C/IGF-I) receptor on cultured human fibroblast monolayers: regulation of receptor concentrations by SM-C/IGF-I and insulin. J Clin Endocrinol Metab (1982) 1.18
Serum insulin-like growth factors I and II concentrations and growth hormone and insulin responses to arginine infusion in children with protein-energy malnutrition before and after nutritional rehabilitation. Pediatr Res (1986) 1.17
Ligand-independent oligomerization of natriuretic peptide receptors. Identification of heteromeric receptors and a dominant negative mutant. J Biol Chem (1992) 1.17
Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol (1996) 1.17
Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2. J Biol Chem (2001) 1.17
Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem (1995) 1.17
Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology (1999) 1.16
Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol Endocrinol (2004) 1.16
EMS Agenda for the Future: where we are...where we want to be. Prehosp Emerg Care (1998) 1.16
Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res (1999) 1.16
Further delineation of aortic dilation, dissection, and rupture in patients with Turner syndrome. Pediatrics (1998) 1.15
Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene (1998) 1.15
Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res (2000) 1.14
Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis (1997) 1.13
Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A (1989) 1.13
Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome. Hum Mutat (1992) 1.13
Global gene expression during nitrogen starvation in the rice blast fungus, Magnaporthe grisea. Fungal Genet Biol (2006) 1.13
Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem (1993) 1.13
The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein. Mol Endocrinol (1988) 1.13
An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis. Clin Nephrol (1994) 1.12
A prospective, randomized study of testosterone treatment of constitutional delay of growth and development in male adolescents. Pediatrics (1982) 1.12
Response elements of the androgen-regulated C3 gene. J Biol Chem (1992) 1.10
The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol (2001) 1.08
The IGF axis in the prostate. Horm Metab Res (1994) 1.08
Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab (1997) 1.08
EMS agenda for the future: where we are ... where we want to be. EMS Agenda for the Future Steering Committee. Ann Emerg Med (1998) 1.07
A SHOX to the system. J Clin Endocrinol Metab (2001) 1.07